BusinessAI imageBenitec Biopharma Reports Full Year 2026 Financial Results and Operational Update
Benitec Biopharma announced its full year 2026 financial results and provided an operational update. All six patients in Cohort 1 (low dose BB-301) have completed the 12-month post-treatment follow-up, and Cohort 2 (high dose BB-301) is fully enrolled, marking significant progress in their clinical trials.
Menafn·

